Gryphus Diagnostics, LLC is focus on the development and manufacture of rapid detection systems. The first of many of these new technologies was FDA released in May 2000, leading the way for a host of other products undergoing investigation. In early 2003, the Company was issued a U.S. patent covering its sialidase technology platform. Gryphusâproducts are registered and/or have regulatory approval in several countries worldwide and marketed globally to point-of-care facilities, hospitals, and clinical laboratories through a network of established distributors and licensees. Company is ISO 9001:2000, ISO 13485:1996, and CMDCAS registered by Underwriters Laboratories to international standards and operates under very strict guidelines set forth by the FDA. The manufacturing plant is a cGMP facility with laboratories employing state-of-the-art equipment and highly trained, skilled individuals. This combination of an ideal scientific environment with expertise in a wide variety of disciplines has resulted in a synergistic explosion of advancements
